v3.26.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Cash flows from operating activities:    
Net income $ 193,446 $ 151,700
Adjustments to reconcile net income to net cash flows from operating activities:    
Depreciation, amortization and accretion 45,265 26,857
Adjustment to the fair value of asset retirement obligation 0 (4,727)
Amortization of debt-related costs 2,230 2,230
Change in fair value of contingent liabilities (31,755) 0
Inventory adjustments 1,991 936
Stock-based compensation 36,048 43,519
Unrealized (gain) loss on investment in equity securities (5,369) 289
Charges incurred pursuant to acquired in-process research and development 0 5,413
Deferred taxes 6,256 (5,577)
Long-term income tax payable and other long-term liabilities 687 (3)
Gain on sale of business, net of transaction costs (59,527) 0
Gain on conversion of Installment Note (2,525) 0
Other (3,314) 3,263
Changes in operating assets and liabilities, excluding impact of acquisitions:    
Accounts receivable 1,044 (28,651)
Inventory 5,414 (5,410)
Other current and noncurrent assets 4,844 (1,916)
Accounts payable 1,580 9,365
Accrued expenses and other current and noncurrent liabilities 21,015 (2,619)
Net cash provided by operating activities 217,330 194,669
Cash flows from investing activities:    
Capital expenditures (5,561) (16,679)
Acquisition of in-process research and development 0 (5,413)
Proceeds from sale of business, net of transaction costs 24,212 0
Proceeds from sale of assets 5,000 0
Purchases of investment in equity securities 0 (5,000)
Net cash provided by (used in) investing activities 23,963 (296,190)
Cash flows from financing activities:    
Payments of long-term debt and other borrowings (464) (465)
Proceeds from stock option exercises 8,553 6,331
Proceeds from employee stock purchase plan 2,590 1,983
Payments for minimum statutory tax withholding related to net share settlement of equity awards (17,797) (24,481)
Repurchase of common stock 0 (100,000)
Net cash used in financing activities (7,118) (116,632)
Effect of exchange rate changes on cash, cash equivalents and restricted cash 14 929
Net increase (decrease) in cash, cash equivalents and restricted cash 234,189 (217,224)
Cash, cash equivalents and restricted cash, beginning of period 360,826 914,486
Cash, cash equivalents and restricted cash, end of period 595,015 697,262
Reconciliation to amounts within the condensed consolidated balance sheets    
Cash and cash equivalents 593,298 695,572
Restricted cash included in other long-term assets 1,717 1,690
Cash, cash equivalents and restricted cash at end of period 595,015 697,262
Schedule of non-cash investing and financing activities    
Additions of property, plant and equipment included in liabilities 2,207 6,834
Modification of lease agreement 1,939 5,789
Receipt of notes related to sale of business 94,000 0
Conversion of notes receivable into preferred stock 70,000 0
Contingent consideration assets related to sale of business 6,500 0
Contingent consideration liabilities related to the acquisition of Evergreen 0 43,042
Excise tax payable on net common stock repurchases 0 245
Right-of-use asset obtained in exchange for operating lease obligation 4,822 0
Right-of-use asset obtained in exchange for finance lease obligation 316 150
Lantheus Biosciences Ltd    
Cash flows from investing activities:    
Acquisition, net of cash acquired 312 0
Evergreen Theragnostics    
Cash flows from investing activities:    
Acquisition, net of cash acquired $ 0 $ (269,098)